Monitoring Sarcopenia With Incretin Receptor Activator Treatment
- PMID: 40530788
- PMCID: PMC12175196
- DOI: 10.1111/1753-0407.70117
Monitoring Sarcopenia With Incretin Receptor Activator Treatment
Conflict of interest statement
The author declares no conflicts of interest.
Figures
References
-
- World Obesity Federation , “World Obesity Atlas 2023,” https://data.worldobesity.org/publications/?cat=19.
-
- Badve S. V., Bilal A., Lee M. M. Y., et al., “Effects of GLP‐1 Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta‐Analysis of Randomised Controlled Trials,” Lancet Diabetes & Endocrinology 13, no. 1 (2025): 15–28. - PubMed
-
- Gallagher D., Visser M., De Meersman R. E., et al., “Appendicular Skeletal Muscle Mass: Effects of Age, Gender, and Ethnicity,” Journal of Applied Physiology 83, no. 1 (1997): 229–239. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
